A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea

Launched by MAYO CLINIC · Oct 6, 2017

Keywords

ClinConnect Summary

This clinical trial is studying how obstructive sleep apnea (OSA) affects fat tissue in adults. OSA is a condition where a person's breathing repeatedly stops and starts during sleep, and it can increase the risk of heart disease, especially in individuals who are overweight. Researchers want to understand the changes in fat tissue that occur with sleep apnea to learn more about its impact on heart health.

To participate in this study, you must be between the ages of 65 and 74, have a body mass index (BMI) of 40 or less, and not be a current smoker. If you have controlled high blood pressure or certain other health conditions, you may still be eligible. Participants will undergo a procedure to take a small sample of fat tissue, which can sound a bit intimidating, but the study team will guide you through everything and ensure you understand what to expect. It's important to note that if you take specific medications or have certain health issues, you might not be able to join. This study is currently recruiting participants, so if you're interested, you can reach out to the study team for more details.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • BMI ≤40 kg/m2
• • Not a current smoker or tobacco user
• • Individuals with treated hypertension, prehypertension, and dyslipidemia will be allowed to participate in the study
• • On no prescription medications other than those medications used to treat asthma, seasonal or environmental allergies (such as Cetirizine, Fexofenadine, Desloratadine, Loratadine, etc), depression, acid reflux (such as antacids or proton pump inhibitors), topical skin treatment medications or shampoos, contraceptive pills, or intrauterine devices. Other medications may be allowed at the discretion of the study staff.
• • Not pregnant or breast feeding and not intending to become pregnant or breast feed
• • Ability to provide written informed consent
• • If a subject is on aspirin or any other anti-inflammatory medication but free of known vascular disease and depending on the indication, the study doctor may ask the subject to suspend aspirin or anti-inflammatory therapy for 7 days prior to participation in the study. In the event that the subject does not stop the aspirin or other anti-inflammatory medication, they will not be able to participate in the study because of the risk of bleeding during the fat biopsy.
• • Exclusion Criteria
• • Vulnerable study population will be excluded
• • Presence of chronic kidney disease (creatinine \>2.5 mg/dL) and/or active cancers
• • Pregnancy
• • Anemic (hemoglobin \<12 g/dL for men and \<11 g/dL for women)
• • Smoking
• • Use of chronic medications (statins, anti-inflammatory drugs, angiotensin II receptor blockers (ARBs) and/or angiotensin-converting enzyme (ACE) inhibitors)
• • Blood or plasma donation during the past 2 months